AR094779A1 - Cetuximab con glicosilación modificada y sus usos - Google Patents
Cetuximab con glicosilación modificada y sus usosInfo
- Publication number
- AR094779A1 AR094779A1 ARP140100458A ARP140100458A AR094779A1 AR 094779 A1 AR094779 A1 AR 094779A1 AR P140100458 A ARP140100458 A AR P140100458A AR P140100458 A ARP140100458 A AR P140100458A AR 094779 A1 AR094779 A1 AR 094779A1
- Authority
- AR
- Argentina
- Prior art keywords
- sec
- glycosylated
- population
- composition
- produced
- Prior art date
Links
- 229960005395 cetuximab Drugs 0.000 title 1
- 238000004113 cell culture Methods 0.000 abstract 2
- 210000005075 mammary gland Anatomy 0.000 abstract 2
- 210000004216 mammary stem cell Anatomy 0.000 abstract 2
- 230000009261 transgenic effect Effects 0.000 abstract 2
- 241000283707 Capra Species 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000002919 epithelial cell Anatomy 0.000 abstract 1
- 201000010536 head and neck cancer Diseases 0.000 abstract 1
- 208000014829 head and neck neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/102—Caprine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Reivindicación 1: Un anticuerpo glicosilado que comprende: (a) una cadena pesada que comprende SEC. ID. Nº 1; (b) una cadena liviana que comprende SEC. ID. Nº 2; donde el anticuerpo glicosilado tiene menos restos de galactosa-a-1,3-galactosa que el anticuerpo glicosilado producido en cultivo de células no mamarias. Reivindicación 13: Una composición que comprende una población de anticuerpos glicosilados, donde el anticuerpo glicosilado comprende: (a) una cadena pesada que comprende SEC. ID. Nº 1; (b) una cadena liviana que comprende SEC. ID. Nº 2; y donde la población de anticuerpos tiene menos restos de galactosa-a-1,3-galactosa que la población de anticuerpos glicosilados producidos en cultivo de células no mamarias. Reivindicación 26: Una composición que comprende anticuerpos monoclonales, donde los anticuerpos monoclonales comprenden: (a) una cadena pesada que comprende SEC. ID. Nº 1; (b) una cadena liviana que comprende SEC. ID. Nº 2; y donde la composición es producida en una glándula mamaria de una cabra transgénica. Reivindicación 43: Un mamífero no humano transgénico que comprende las células epiteliales de la glándula mamaria de cualquiera de las reivindicaciones 40 - 42. Reivindicación 51: El método de la reivindicación 50, donde el cáncer es cáncer de cabeza y cuello o cáncer colorrectal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764446P | 2013-02-13 | 2013-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR094779A1 true AR094779A1 (es) | 2015-08-26 |
Family
ID=50980328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140100458A AR094779A1 (es) | 2013-02-13 | 2014-02-13 | Cetuximab con glicosilación modificada y sus usos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160002330A1 (es) |
| EP (1) | EP2956484B1 (es) |
| JP (1) | JP2016513105A (es) |
| KR (1) | KR20150145225A (es) |
| CN (1) | CN105358577A (es) |
| AR (1) | AR094779A1 (es) |
| AU (1) | AU2014217569B2 (es) |
| BR (1) | BR112015019339A2 (es) |
| CA (1) | CA2900915A1 (es) |
| IL (1) | IL240442A0 (es) |
| MX (1) | MX2015010429A (es) |
| TW (1) | TW201444871A (es) |
| WO (1) | WO2014125382A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112076330B (zh) | 2010-12-30 | 2023-06-02 | 法国化学与生物科技实验室 | 作为病原体灭活剂的二元醇 |
| CN105263319A (zh) | 2013-02-13 | 2016-01-20 | 法国化学与生物科技实验室 | 具有经修饰的糖基化的蛋白及其生产方法 |
| BR112015019341A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal |
| CA2916566A1 (fr) | 2013-07-05 | 2015-01-08 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Matrice de chromatographie d'affinite |
| US10233454B2 (en) | 2014-04-09 | 2019-03-19 | Dna2.0, Inc. | DNA vectors, transposons and transposases for eukaryotic genome modification |
| HUE056009T2 (hu) | 2015-10-08 | 2022-01-28 | Dna Twopointo Inc | DNS vektorok, transzpozonok és transzpozázok eukarióta genom módosítására |
| JP2019508380A (ja) * | 2016-01-10 | 2019-03-28 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Ｅｇｆｒに対するグリコシル化キメラ抗体での癌の処置のための改善された安全性 |
| CN109415441B (zh) * | 2016-05-24 | 2023-04-07 | 英斯梅德股份有限公司 | 抗体及其制备方法 |
| KR102376545B1 (ko) * | 2017-08-01 | 2022-03-21 | 삼성디스플레이 주식회사 | 플렉시블 디스플레이 윈도우 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| IL165088A0 (en) * | 2002-05-17 | 2005-12-18 | Kirin Brewery | Transgenic ungulates capable of human antibody production |
| WO2004050847A2 (en) * | 2002-11-27 | 2004-06-17 | Gtc Biotherapeutics, Inc. | Modified antibodies stably produced in milk and methods of producing same |
| CA2450289A1 (en) * | 2003-03-20 | 2005-05-19 | Imclone Systems Incorporated | Method of producing an antibody to epidermal growth factor receptor |
| US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| CA2583017A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
| MX342271B (es) | 2005-05-18 | 2016-09-21 | Ablynx Nv | Nanobodiestm (nanocuerpos) mejorados contra el factor alfa de necrosis del tumor. |
| EP2388273B1 (en) | 2005-10-21 | 2017-07-05 | LFB USA, Inc. | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
| FR2901707B1 (fr) * | 2006-05-31 | 2017-09-29 | Lab Francais Du Fractionnement | Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis |
| AU2007294122B2 (en) * | 2006-09-10 | 2013-03-07 | Glycotope Gmbh | Use of human cells of myeloid leukaemia origin for expression of antibodies |
| WO2008101177A2 (en) * | 2007-02-16 | 2008-08-21 | University Of Virginia Patent Foundation | Ige antibodies to chimeric or humanized igg therapeutic monoclonal antibodies as a screening test for anaphylaxis |
| AU2009338190C1 (en) * | 2009-01-22 | 2014-07-17 | Momenta Pharmaceuticals, Inc. | Galactose-alpha-1, 3-galactose-containing N-glycans in glycoprotein products derived from CHO cells |
| JP2013510574A (ja) * | 2009-11-11 | 2013-03-28 | モメンタ ファーマシューティカルズ インコーポレイテッド | チャイニーズハムスターからのグリコシルトランスフェラーゼおよび関連方法 |
-
2014
- 2014-02-13 AU AU2014217569A patent/AU2014217569B2/en not_active Ceased
- 2014-02-13 CA CA2900915A patent/CA2900915A1/en not_active Abandoned
- 2014-02-13 WO PCT/IB2014/000867 patent/WO2014125382A2/en active Application Filing
- 2014-02-13 CN CN201480018266.7A patent/CN105358577A/zh active Pending
- 2014-02-13 BR BR112015019339A patent/BR112015019339A2/pt not_active Application Discontinuation
- 2014-02-13 US US14/767,089 patent/US20160002330A1/en not_active Abandoned
- 2014-02-13 AR ARP140100458A patent/AR094779A1/es unknown
- 2014-02-13 JP JP2015557534A patent/JP2016513105A/ja active Pending
- 2014-02-13 MX MX2015010429A patent/MX2015010429A/es unknown
- 2014-02-13 KR KR1020157024950A patent/KR20150145225A/ko not_active Application Discontinuation
- 2014-02-13 TW TW103104778A patent/TW201444871A/zh unknown
- 2014-02-13 EP EP14732006.3A patent/EP2956484B1/en not_active Not-in-force
-
2015
- 2015-08-09 IL IL240442A patent/IL240442A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015019339A2 (pt) | 2017-08-22 |
| US20160002330A1 (en) | 2016-01-07 |
| AU2014217569A1 (en) | 2015-08-27 |
| AU2014217569B2 (en) | 2018-10-25 |
| IL240442A0 (en) | 2015-09-24 |
| WO2014125382A2 (en) | 2014-08-21 |
| JP2016513105A (ja) | 2016-05-12 |
| CA2900915A1 (en) | 2014-08-21 |
| EP2956484A2 (en) | 2015-12-23 |
| MX2015010429A (es) | 2016-05-16 |
| KR20150145225A (ko) | 2015-12-29 |
| WO2014125382A3 (en) | 2014-11-06 |
| TW201444871A (zh) | 2014-12-01 |
| EP2956484B1 (en) | 2018-11-14 |
| CN105358577A (zh) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR094779A1 (es) | Cetuximab con glicosilación modificada y sus usos | |
| CY1121217T1 (el) | Μεθοδοι για συγκομιδη καλλιεργειων κυτταρου θηλαστικων | |
| CO2019003945A2 (es) | Proteínas de fusión heterodiméricas biespecíficas que contienen proteínas de fusión fc il-15/il-15rα y fragmentos de anticuerpo pd-1 | |
| AR101844A1 (es) | Anticuerpos y conjugados modificados genéticamente con cisteína | |
| AR094375A1 (es) | Métodos de uso de inhibidores del ciclo celular para modular una o más propiedades de un cultivo celular | |
| PE20210107A1 (es) | Anticuerpos anti-cd3 y metodos de uso | |
| CL2016001068A1 (es) | Producción de inmunoglobinas de heterodiméricas de redireccionamiento de células t | |
| AR098465A1 (es) | ANTICUERPOS ANTI-a-SINUCLEÍNA Y MÉTODOS DE UTILIZACIÓN | |
| CL2017000278A1 (es) | Moléculas biespecíficas de unión a antígeno activadoras de células t | |
| BR112015019341A2 (pt) | Anticorpo anti-tnf-alfa, composição que compreende o anticorpo, método para produzir uma população de anticorpos, células epiteliais da glândula mamária, mamífero não humano transgênico, e, composição de anticorpo anti-tnf monoclonal | |
| CY1117797T1 (el) | Μεθοδοι ενδοκυτταρικης μετατροπης πρωτεϊνων μονης αλυσιδας προς τη μορφη διπλης αλυσιδας αυτων | |
| BR112012026766A2 (pt) | métodos in vitro para gerar uma proteína heterodimérica, para a seleção de um anticorpo biespecífico e para inibir o crescimento, vetor de expressão, célula hospedeira, proteína heterodimérica, composição farmacêutica. | |
| AR094781A1 (es) | Anticuerpos anti-her2 (receptor 2 del factor de crecimiento epidérmico humano) altamente galactosilados y sus usos | |
| CR20110544A (es) | Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7 | |
| EA201400875A1 (ru) | Антитела к cd47 и способы их применения | |
| CO2021001544A2 (es) | Variantes de anticuerpos anti-cd38 y sus usos | |
| AR100367A1 (es) | Anticuerpos biespecíficos químicamente bloqueados | |
| AR102092A1 (es) | Anticuerpos que neutralizan una sustancia que tiene una actividad relacionada con la sustitución de la función del factor de coagulación viii (fviii) | |
| AR095418A1 (es) | Métodos para aumentar el contenido de manosa en proteínas recombinantes | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| EA202190244A3 (ru) | Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков | |
| BR112018015626A2 (pt) | sistema fúngico de produção de alto nível de proteínas | |
| MX2017005930A (es) | Metodo de produccion de proteinas de cadena doble en bacterias. | |
| BR112017023503A2 (pt) | método, composição, e, mamífero transgênico não humano. | |
| EA201690684A1 (ru) | Способ осветления выросшей клеточной массы неочищенной культуры клеток с высокой плотностью клеток |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |